Home Intangible Assets Biodesix, Inc. Reports Unaudited Impairment Loss on Intangible Assets for the First Quarter Ended March 31, 2026

Intangible Assets

Biodesix, Inc. Reports Unaudited Impairment Loss on Intangible Assets for the First Quarter Ended March 31, 2026

ByAmeliaMay 10, 20263 Mins read21

Market Closed – Nasdaq			5-day change	1st Jan Change
15.32 ^USD	-0.97%		+38.27%	+125.29%

Published on 05/04/2026
at 04:01 pm EDT

S&P Capital IQ

Biodesix, Inc. reported unaudited impairment loss on intangible assets for the first quarter ended March 31, 2026. For the quarter, the company reported impairment loss on intangible assets of $5,000 against $73,000 a year ago.

May. 05	Top Premarket Gainers	MT
May. 04	Biodesix, Inc., Q1 2026 Earnings Call, May 04, 2026
May. 04	Biodesix, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
May. 04	Biodesix, Inc. Reports Unaudited Impairment Loss on Intangible Assets for the First Quarter Ended March 31, 2026	CI
May. 04	Biodesix Increases Consolidated Earnings Guidance for the Fiscal Year 2026	CI
Mar. 20	Biodesix Inc Announces Publication of Largest Lung Nodule Biomarker Clinical Validation Study Supporting Earlier Lung Cancer Diagnosis	CI
Mar. 11	Biodesix, Inc. Presents at Barclays 28th Annual Global Healthcare Conference, Mar-11-2026 12:00 PM
Feb. 27	William Blair Upgrades Biodesix to Outperform From Market Perform	MT
Feb. 26	Biodesix, Inc., Q4 2025 Earnings Call, Feb 26, 2026
Feb. 26	Biodesix, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2025	CI
Feb. 26	Biodesix, Inc. Provides Earnings Guidance for the Fiscal Year 2026	CI
Jan. 27	Biodesix Insider Bought Shares Worth $1,180,736, According to a Recent SEC Filing	MT
Jan. 26	Biodesix Insider Bought Shares Worth $903,561, According to a Recent SEC Filing	MT
Jan. 12	Top Midday Gainers	MT
Jan. 12	Top Premarket Gainers	MT

Duration

Period

Biodesix, Inc. is a diagnostic solutions company. It offers two tests (Nodify Lung tests) that assess the risk of cancer in lung nodules and three tests (IQLung tests) that provide treatment guidance after a lung cancer diagnosis. Nodify CDT and Nodify XL2 tests, marketed as Nodify Lung Nodule Risk Assessment, assess the lung nodule’s risk of lung cancer to help identify the appropriate treatment pathway. The Nodify CDT test is a blood-based test that detects the presence of seven autoantibodies associated with the presence of tumors. The Nodify XL2 test is a blood-based proteomic test that evaluates the likelihood that a lung nodule is benign to help identify patients that may benefit from surveillance imaging. GeneStrat ddPCR, GeneStrat NGS and VeriStrat tests, marketed as part of its IQLung testing strategy, are used following diagnosis of lung cancer to detect the presence of mutations in the tumor and the state of the patientâ€™s immune system to help guide treatment decisions.